Skip to Content


Sarah Karlin and Brett Norman, featuring Rachel E. Sachs (Academic Fellow)
Politico
January 19, 2016

Read the Full Round-Up and Link to Rachel's Full Post

REALITY CHECK ON 'MARCH-IN'-RIGHTS — 50 House Democrats wrote HHS and NIH last week that the government should exercise its march-in rights — handing over the patents on some high-priced drugs so that competitors can make cheaper versions. The government can invalidate intellectual property claims that are based on federally-funded research if the benefits of the products aren’t available to the public on “reasonable terms.” The lawmakers believe NIH guidance on when march-in rights would apply could discourage price gouging. Sounds like a good solution — but not so fast. Rachel Sachs, a fellow at Harvard Law School’s Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics, writes. [...]

Read the Full Round-Up and Link to Rachel's Full Post

Tags

fda   health care finance   health law policy   innovation   intellectual property   pharmaceuticals   public health   regulation   research funding